CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Phase 3

Completed

Conditions: Crohn Disease

Interventions: Other: Placebo
Drug: Ozanimod

First Posted Date: 2018-02-22

Last Posted Date: 2024-12-05

Lead Sponsor: Celgene

Target Recruit Count: 606

Registration Number: NCT03440385

Locations: 🇫🇮
Local Institution - 614, Turku, Finland
🇺🇸
Local Institution - 202, Scottsdale, Arizona, United States
🇺🇸
Ucsd Medical Center, La Jolla, California, United States

and more 365 locations

Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain

Completed

Conditions: Leukemia, Myeloid, Acute

First Posted Date: 2018-02-19

Last Posted Date: 2021-05-21

Lead Sponsor: Celgene

Target Recruit Count: 151

Registration Number: NCT03435341

Locations: 🇪🇸
Hospital de León, León, Castilla-León, Spain
🇪🇸
Hospital Virgen de las Nieves, Granada, Andalucía/Granada, Spain
🇪🇸
Hospital Universitario Nuestra Señora de Valme, Sevilla, Andalucía/Sevilla, Spain

and more 37 locations

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Phase 2

Recruiting

Conditions: Neoplasms

Interventions: Genetic: Gene-modified (GM) T cell therapy

First Posted Date: 2018-02-19

Last Posted Date: 2025-05-23

Lead Sponsor: Celgene

Target Recruit Count: 1541

Registration Number: NCT03435796

Locations: 🇸🇪
Karolinska University Hospital Huddinge, Stockholm, Sweden
🇨🇭
Inselspital Bern, Bern, Switzerland
🇬🇧
Local Institution - 10850, Leeds, United Kingdom

and more 176 locations

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: CC-92480
Drug: Dexamethasone

First Posted Date: 2017-12-15

Last Posted Date: 2024-12-16

Lead Sponsor: Celgene

Target Recruit Count: 201

Registration Number: NCT03374085

Locations: 🇺🇸
Local Institution - 103, Duarte, California, United States
🇺🇸
Local Institution - 102, Atlanta, Georgia, United States
🇺🇸
Local Institution - 105, Boston, Massachusetts, United States

and more 51 locations

A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects

Phase 1

Completed

Conditions: Heathy Volunteer

Interventions: Drug: CC-90001
Drug: Omeprazole
Drug: Nintedanib
Drug: Rosuvastatin
Drug: Metformin
Drug: Midazolam
Drug: Digoxin
Drug: Warfarin
Dietary Supplement: Vitamin K

First Posted Date: 2017-12-06

Last Posted Date: 2019-01-25

Lead Sponsor: Celgene

Target Recruit Count: 56

Registration Number: NCT03363815

Locations: 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Biological: bb2121

First Posted Date: 2017-12-05

Last Posted Date: 2025-05-23

Lead Sponsor: Celgene

Target Recruit Count: 149

Registration Number: NCT03361748

Locations: 🇺🇸
University of California - San Francisco, San Francisco, California, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 45 locations

A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia

Phase 2

Completed

Conditions: Thalassemia

Interventions: Other: Placebo
Drug: Luspatercept
Other: Best Supportive Care (BSC)

First Posted Date: 2017-11-17

Last Posted Date: 2023-12-20

Lead Sponsor: Celgene

Target Recruit Count: 145

Registration Number: NCT03342404

Locations: 🇬🇷
Local Institution - 102, Athens, Greece
🇺🇸
Children's Hospital and Research Center at Oakland, Oakland, California, United States
🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States

and more 13 locations

Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: CC-122
Drug: Fluvoxamine
Drug: Rifampin
Drug: Itraconazole

First Posted Date: 2017-11-13

Last Posted Date: 2019-01-16

Lead Sponsor: Celgene

Target Recruit Count: 81

Registration Number: NCT03340662

Locations: 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: CC-90006
Other: Placebo

First Posted Date: 2017-11-08

Last Posted Date: 2020-05-07

Lead Sponsor: Celgene

Target Recruit Count: 34

Registration Number: NCT03337022

Locations: 🇨🇦
Innovaderm Research, Montreal, Quebec, Canada
🇺🇸
TKL Research, Fair Lawn, New Jersey, United States
🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States

and more 1 locations

A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis

Not Applicable

Completed

Conditions: Sarcoidosis, Pulmonary

Interventions: Drug: Glucocorticoid (prednisone or prednisolone)

First Posted Date: 2017-10-27

Last Posted Date: 2020-02-26

Lead Sponsor: Celgene

Target Recruit Count: 8

Registration Number: NCT03324503

Locations: 🇺🇸
Johns Hopkins University School of Medicine - Baltimore, Baltimore, Maryland, United States
🇳🇱
Catharina Ziekenhuis, Eindhoven, Netherlands
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

and more 17 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy